Editorial (Hot Topic Potential Value and Limitation of Dual Inhibitors of PI3K and mTOR in the Treatment of Cancer)

E-ISSN： 1873-5576|13|2|117-120

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.13, Iss.2, 2013-02, pp. : 117-120

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial (Hot Topic: PI3K/AKT and mTOR/p70S6K1 Signaling Pathways in Human Cancer)

Current Cancer Drug Targets, Vol. 13, Iss. 3, 2013-03 ,pp. : 233-233

Bentham Science Publishers

Access to resources Recommend Favorite

Dual Inhibitors of PI3K/mTOR or mTOR-Selective Inhibitors: Which Way Shall We Go?

Current Medicinal Chemistry, Vol. 18, Iss. 36, 2011-12 ,pp. : 5528-5544

Bentham Science Publishers

Access to resources Recommend Favorite

PI3K/AKT/mTOR Inhibitors In Ovarian Cancer

Current Medicinal Chemistry, Vol. 17, Iss. 36, 2010-12 ,pp. : 4433-4447

Bentham Science Publishers

Access to resources Recommend Favorite

mTOR inhibitors in the treatment of cancer

By Fasolo Angelica Sessa Cristiana

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 11, 2008-11 ,pp. : 1717-1734

Informa Healthcare

Access to resources Recommend Favorite